View ValuationMedicure 将来の成長Future 基準チェック /06現在、 Medicureの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長-11.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.0m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Market cap is less than US$10m (CA$11.5m market cap, or US$8.31m).お知らせ • May 22Medicure Inc. to Report Q1, 2026 Results on May 21, 2026Medicure Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 21, 2026Reported Earnings • Apr 26Full year 2025 earnings released: EPS: CA$0.68 (vs CA$0.10 loss in FY 2024)Full year 2025 results: EPS: CA$0.68. Revenue: CA$28.9m (up 32% from FY 2024). Net loss: CA$7.10m (loss widened CA$6.06m from FY 2024).お知らせ • Mar 10Medicure Inc., Annual General Meeting, May 21, 2026Medicure Inc., Annual General Meeting, May 21, 2026. Location: manitoba, winnipeg CanadaReported Earnings • Nov 21Third quarter 2025 earnings released: CA$0.13 loss per share (vs CA$0.065 profit in 3Q 2024)Third quarter 2025 results: CA$0.13 loss per share (down from CA$0.065 profit in 3Q 2024). Revenue: CA$8.16m (up 58% from 3Q 2024). Net loss: CA$1.40m (down 305% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.お知らせ • Nov 14Medicure Inc. to Report Q3, 2025 Results on Nov 19, 2025Medicure Inc. announced that they will report Q3, 2025 results After-Market on Nov 19, 2025分析記事 • Nov 11Medicure Inc. (CVE:MPH) Surges 29% Yet Its Low P/S Is No Reason For ExcitementMedicure Inc. ( CVE:MPH ) shares have had a really impressive month, gaining 29% after a shaky period beforehand. The...Reported Earnings • Aug 22Second quarter 2025 earnings released: CA$0.08 loss per share (vs CA$0.12 loss in 2Q 2024)Second quarter 2025 results: CA$0.08 loss per share (improved from CA$0.12 loss in 2Q 2024). Revenue: CA$6.67m (up 29% from 2Q 2024). Net loss: CA$786.0k (loss narrowed 35% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.お知らせ • Aug 19Medicure Inc. to Report Q2, 2025 Results on Aug 20, 2025Medicure Inc. announced that they will report Q2, 2025 results After-Market on Aug 20, 2025Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Director James Kinley was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.分析記事 • Jun 21There's No Escaping Medicure Inc.'s (CVE:MPH) Muted Revenues Despite A 26% Share Price RiseMedicure Inc. ( CVE:MPH ) shareholders would be excited to see that the share price has had a great month, posting a...分析記事 • May 14This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medicure Inc.'s (CVE:MPH) CEOKey Insights Medicure will host its Annual General Meeting on 21st of May Salary of CA$264.0k is part of CEO Albert...分析記事 • May 07Medicure Inc. (CVE:MPH) Stock Catapults 28% Though Its Price And Business Still Lag The IndustryMedicure Inc. ( CVE:MPH ) shareholders would be excited to see that the share price has had a great month, posting a...Reported Earnings • Apr 26Full year 2024 earnings released: CA$0.10 loss per share (vs CA$0.088 loss in FY 2023)Full year 2024 results: CA$0.10 loss per share (further deteriorated from CA$0.088 loss in FY 2023). Revenue: CA$21.9m (up 1.0% from FY 2023). Net loss: CA$1.04m (loss widened 13% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.お知らせ • Apr 23Medicure Inc. to Report Fiscal Year 2024 Results on Apr 28, 2025Medicure Inc. announced that they will report fiscal year 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025分析記事 • Mar 12Medicure Inc.'s (CVE:MPH) Shares Lagging The Industry But So Is The BusinessWhen you see that almost half of the companies in the Biotechs industry in Canada have price-to-sales ratios (or "P/S...お知らせ • Mar 12Medicure Inc., Annual General Meeting, May 21, 2025Medicure Inc., Annual General Meeting, May 21, 2025. Location: manitoba, winnipeg CanadaReported Earnings • Nov 26Third quarter 2024 earnings released: EPS: CA$0.07 (vs CA$0.008 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.07 (up from CA$0.008 in 3Q 2023). Revenue: CA$5.15m (up 3.0% from 3Q 2023). Net income: CA$680.0k (up CA$596.0k from 3Q 2023). Profit margin: 13% (up from 1.7% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 2% per year.お知らせ • Nov 22Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of DirectorsMedicure Inc. announced that Kimberly Kramchynsky, a member of the Board of Directors, has resigned for personal reasons, effective November 18, 2024.お知らせ • Nov 19Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024Medicure Inc. announced that they will report Q3, 2024 results After-Market on Nov 25, 2024Reported Earnings • Aug 16Second quarter 2024 earnings released: CA$0.12 loss per share (vs CA$0.024 profit in 2Q 2023)Second quarter 2024 results: CA$0.12 loss per share (down from CA$0.024 profit in 2Q 2023). Revenue: CA$5.17m (down 14% from 2Q 2023). Net loss: CA$1.22m (down CA$1.47m from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.分析記事 • Jul 31Medicure Inc.'s (CVE:MPH) Price Is Right But Growth Is LackingMedicure Inc.'s ( CVE:MPH ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy right now...Buy Or Sell Opportunity • Jul 17Now 35% undervalued after recent price dropOver the last 90 days, the stock has fallen 2.9% to CA$1.00. The fair value is estimated to be CA$1.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.お知らせ • May 30Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as DirectorMedicure Inc. announced the voting results for the election of directors at its annual meeting of shareholders held earlier May 28, 2024 approved Kimberly Kramchynsky, more commonly known as Kim Kline, is the only newly appointed director. Ms. Kline is currently on the board of BioTalent Canada and the advisory board of RRC Polytech Life Sciences. She is also the past President of the Bioscience Association of Manitoba, a position she held until early 2024, and a former member of the University of Manitoba Faculty of Science Dean's advisory board.Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: CA$5.69m (up 1.2% from 1Q 2023). Net income: CA$51.0k (down 82% from 1Q 2023). Profit margin: 0.9% (down from 5.2% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • May 14Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to CA$1.06. The fair value is estimated to be CA$1.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Meanwhile, the company became loss making.分析記事 • May 14Estimating The Fair Value Of Medicure Inc. (CVE:MPH)Key Insights Using the 2 Stage Free Cash Flow to Equity, Medicure fair value estimate is CA$1.40 Current share price of...お知らせ • Apr 21Medicure Inc., Annual General Meeting, May 28, 2024Medicure Inc., Annual General Meeting, May 28, 2024.Reported Earnings • Apr 12Full year 2023 earnings released: CA$0.088 loss per share (vs CA$0.13 profit in FY 2022)Full year 2023 results: CA$0.088 loss per share (down from CA$0.13 profit in FY 2022). Revenue: CA$21.7m (down 5.9% from FY 2022). Net loss: CA$922.0k (down 168% from profit in FY 2022). Products in clinical trials Phase III: 1 Post-clinical trial products Pre-registration: 1 Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.お知らせ • Apr 05Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024Medicure Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Apr 08, 2024分析記事 • Mar 08Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) TunnelWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") above 15x, you may consider...New Risk • Jan 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (CA$12.0m market cap, or US$8.90m). Minor Risk Profit margins are more than 30% lower than last year (4.7% net profit margin).New Risk • Jan 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$11.1m (US$8.24m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$11.1m market cap, or US$8.24m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Profit margins are more than 30% lower than last year (4.7% net profit margin).Valuation Update With 7 Day Price Move • Jan 15Investor sentiment deteriorates as stock falls 24%After last week's 24% share price decline to CA$1.06, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 18x in the Biotechs industry in North America. Total loss to shareholders of 23% over the past three years.Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CA$1.32, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 17x in the Biotechs industry in North America. Total returns to shareholders of 55% over the past three years.お知らせ • Nov 24Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric DiseaseMedicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphateoxidase (PNPO) deficiency. The study involves approximately 10 patients at sites in the United States and Australia, and the Company is seeking marketing approval initially in those countries. The U.S. Food and Drug Administration ("FDA") has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency ("EMA") has granted Orphan Drug Designation toMC-1 for the treatment of PNPO deficiency. Under the Food and Drug Administration Safety and Innovation Act (FDASIA) passed into federal law in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals from birth to 18 years of age, with a prevalence of less than 200,000 people in the United States. If a new drug application ("NDA") for MC-1 for patients with PNPO deficiency is approved, the Company may be eligible to receive a priority review voucher ("PRV") from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application.Reported Earnings • Nov 24Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.11 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.01 (down from CA$0.11 in 3Q 2022). Revenue: CA$5.00m (down 5.4% from 3Q 2022). Net income: CA$84.0k (down 93% from 3Q 2022). Profit margin: 1.7% (down from 21% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.New Risk • Nov 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (CA$15.7m market cap, or US$11.4m).New Risk • Nov 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (CA$14.8m market cap, or US$10.7m).Valuation Update With 7 Day Price Move • Oct 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CA$1.50, the stock trades at a trailing P/E ratio of 7.4x. Average trailing P/E is 15x in the Biotechs industry in North America. Total returns to shareholders of 88% over the past three years.分析記事 • Aug 28We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Reported Earnings • Jul 30Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.067 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.02 (up from CA$0.067 loss in 2Q 2022). Revenue: CA$5.99m (up 4.3% from 2Q 2022). Net income: CA$253.0k (up CA$936.0k from 2Q 2022). Profit margin: 4.2% (up from net loss in 2Q 2022). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 25Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023Medicure Inc. announced that they will report Q2, 2023 results After-Market on Jul 28, 2023New Risk • Jul 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (CA$13.5m market cap, or US$10.2m).Valuation Update With 7 Day Price Move • Jul 12Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CA$1.13, the stock trades at a trailing P/E ratio of 10.1x. Average trailing P/E is 13x in the Biotechs industry in North America. Total returns to shareholders of 5.6% over the past three years.Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.35, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 12x in the Biotechs industry in North America. Total returns to shareholders of 36% over the past three years.Reported Earnings • May 28First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.047 in 1Q 2022)First quarter 2023 results: EPS: CA$0.03 (down from CA$0.047 in 1Q 2022). Revenue: CA$5.63m (down 1.5% from 1Q 2022). Net income: CA$290.0k (down 40% from 1Q 2022). Profit margin: 5.2% (down from 8.4% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • May 05Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to CA$1.01, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 14x in the Biotechs industry in North America. Total loss to shareholders of 19% over the past three years.Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.39, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 14x in the Biotechs industry in North America. Total loss to shareholders of 17% over the past three years.Reported Earnings • Apr 08Full year 2022 earnings released: EPS: CA$0.13 (vs CA$0.071 loss in FY 2021)Full year 2022 results: EPS: CA$0.13 (up from CA$0.071 loss in FY 2021). Revenue: CA$23.1m (up 6.1% from FY 2021). Net income: CA$1.37m (up CA$2.09m from FY 2021). Profit margin: 5.9% (up from net loss in FY 2021). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.お知らせ • Feb 02Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of DirectorsMedicure Inc. announced that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improved over the past weekAfter last week's 18% share price gain to CA$1.25, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 14x in the Biotechs industry in North America. Total loss to shareholders of 64% over the past three years.Recent Insider Transactions • Dec 23Founder recently bought CA$67k worth of stockOn the 16th of December, Albert Friesen bought around 67k shares on-market at roughly CA$1.00 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Albert has been a buyer over the last 12 months, purchasing a net total of CA$184k worth in shares.分析記事 • Nov 30Medicure's (CVE:MPH) Earnings Are Weaker Than They SeemMedicure Inc.'s ( CVE:MPH ) robust earnings report didn't manage to move the market for its stock. We did some digging...Reported Earnings • Nov 25Third quarter 2022 earnings released: EPS: CA$0.11 (vs CA$0.092 loss in 3Q 2021)Third quarter 2022 results: EPS: CA$0.11 (up from CA$0.092 loss in 3Q 2021). Revenue: CA$5.29m (up 7.5% from 3Q 2021). Net income: CA$1.11m (up CA$2.06m from 3Q 2021). Profit margin: 21% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.お知らせ • Nov 18Medicure Inc. to Report Q3, 2022 Results on Nov 25, 2022Medicure Inc. announced that they will report Q3, 2022 results on Nov 25, 2022Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Independent Director Brent Fawkes was the last director to join the board, commencing their role in 2013. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 25Second quarter 2022 earnings released: CA$0.067 loss per share (vs CA$0.062 loss in 2Q 2021)Second quarter 2022 results: CA$0.067 loss per share (down from CA$0.062 loss in 2Q 2021). Revenue: CA$5.75m (up 13% from 2Q 2021). Net loss: CA$683.0k (loss widened 6.9% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improved over the past weekAfter last week's 44% share price gain to CA$1.37, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 16x in the Biotechs industry in North America. Total loss to shareholders of 70% over the past three years.お知らせ • Aug 18Medicure Inc. to Report Q2, 2022 Results on Aug 24, 2022Medicure Inc. announced that they will report Q2, 2022 results After-Market on Aug 24, 2022Valuation Update With 7 Day Price Move • Jul 27Investor sentiment improved over the past weekAfter last week's 29% share price gain to CA$1.16, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 16x in the Biotechs industry in North America. Total loss to shareholders of 77% over the past three years.お知らせ • Jun 21Medicure Inc. Appoints James Kinley as DirectorMedicure Inc. announced that James Kinley was elected as director at its Annual General Meeting of shareholders held on June 16, 2022.Reported Earnings • Jun 01First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: EPS: CA$0.047 (up from CA$0.10 loss in 1Q 2021). Revenue: CA$5.72m (up 16% from 1Q 2021). Net income: CA$482.0k (up CA$1.53m from 1Q 2021). Profit margin: 8.4% (up from net loss in 1Q 2021). Revenue missed analyst estimates by 46%. Earnings per share (EPS) exceeded analyst estimates. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.お知らせ • May 31Medicure Inc. Appoints Haaris Uddin as Chief Financial Officer, Effective June 1, 2022Medicure Inc. announced the appointment of Mr. Haaris Uddin (CPA, B.Comm.) as Chief Financial Officer, effective June 1, 2022. Mr. Uddin as Chief Financial Officer, he began his career with Ernst & Young LLP as a senior accountant in assurance services and brings experience in public company reporting within the life sciences industry in both Canada and the United States.Reported Earnings • Apr 29Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: CA$0.07 loss per share (up from CA$0.64 loss in FY 2020). Revenue: CA$21.7m (up 87% from FY 2020). Net loss: CA$727.0k (loss narrowed 89% from FY 2020). Post-clinical trial products Pre-registration: 1 Revenue missed analyst estimates by 46%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.Board Change • Apr 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Independent Director Brent Fawkes was the last director to join the board, commencing their role in 2013. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 16Medicure Inc., Annual General Meeting, Jun 16, 2022Medicure Inc., Annual General Meeting, Jun 16, 2022.お知らせ • Nov 24Medicure Plans to Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly to Millions of AmericansMedicure Inc. announced that it is planning to launch a national direct-to-consumer E-Commerce pharmacy platform through its subsidiary, Marley Drug™ pharmacy, before the end of 2021. Marley Drug's new E-Commerce website will be a platform where FDA approved medications can be purchased at discount prices by Americans for home delivery in all 50 States, including ZYPITAMAG® (pitavastatin) tablets. A primary goal of the platform is to bypass the traditional framework run by health insurers and pharmacy benefit managers that have made access to affordable medications challenging for many Americans, including both generic and branded products such as ZYPITAMAG. More than 120 million uninsured and underinsured Americans struggle to access affordable medications and are looking for a trusted and convenient source to fill their prescriptions. Marley Drug will offer industry leading pricing on more than 100 of the most commonly prescribed generic medications with free nationwide delivery. The platform will focus on ease-of-use and customer service, and is differentiated by being able to ship to every US state. Notably, the pharmacy platform addresses 'pharmacy deserts' that exist across the country. A 'pharmacy desert' is defined as a geographic area where Americans can't fill a prescription within a half-a-mile of their homes (for low-income people without cars), and a mile for others. This lack of quick access to a pharmacy affects many Americans.Reported Earnings • Nov 24Third quarter 2021 earnings: EPS and revenues miss analyst expectationsThird quarter 2021 results: CA$0.09 loss per share (up from CA$0.098 loss in 3Q 2020). Revenue: CA$4.92m (up 39% from 3Q 2020). Net loss: CA$946.0k (loss narrowed 9.6% from 3Q 2020). Revenue missed analyst estimates by 46%. Earnings per share (EPS) also missed analyst estimates by 100%. Earnings per share (EPS) missed analyst estimates by 100%. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 42% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 28Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.002 profit in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$5.09m (up 90% from 2Q 2020). Net loss: CA$639.0k (down CA$658.0k from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 33 percentage points per year, which is a significant difference in performance.分析記事 • Jun 15Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More CloselyThe results at Medicure Inc. ( CVE:MPH ) have been quite disappointing recently and CEO Albert Friesen bears some...Executive Departure • May 18CFO & Secretary has left the companyOn the 15th of May, James Kinley's tenure in the role of CFO & Secretary ended. As of December 2020, James personally held only 47.10k shares (CA$56k worth at the time). James is the only executive to leave the company over the last 12 months.Reported Earnings • May 12First quarter 2021 earnings releasedThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$4.94m (up 64% from 1Q 2020). Net loss: CA$1.05m (loss narrowed 28% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.Reported Earnings • Apr 24Full year 2020 earnings releasedThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: CA$11.6m (down 42% from FY 2019). Net loss: CA$6.85m (loss narrowed 65% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.Is New 90 Day High Low • Feb 23New 90-day high: CA$1.70The company is up 127% from its price of CA$0.75 on 24 November 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.お知らせ • Jan 28Medicure Announces Early Completion of Enrollment for iSPASMMedicure Inc. announce the early completion of iSPASM, a randomized, double-blind, single-center, Phase 1/2a trial aimed at assessing the safety of long-term (7-day) use of AGGRASTAT® (tirofiban hydrochloride) injection (an intravenous GP IIb/IIIa inhibitor) vs. placebo in patients with aneurysmal subarachnoid hemorrhage (aSAH) (NCT03691727). The primary endpoint in the 30 patient study was hemorrhagic changes evident on head CT and/or MRI assessed by the rates of symptomatic and asymptomatic bleeding. iSPASM was funded by an unrestricted educational grant from Medicure. This study does not imply efficacy of AGGRASTAT® in patients with aSAH. Please note that the use of AGGRASTAT® in neurointerventions has not been approved by the FDA. As of this time, neither AGGRASTAT® nor any of the GP IIb/IIIa inhibitors are indicated for the use in stroke patients. AGGRASTAT® is approved for use in NSTE-ACS patients. Refer to Important Safety Information below and the U.S. Prescribing Information for complete product information.Is New 90 Day High Low • Jan 23New 90-day high: CA$1.65The company is up 81% from its price of CA$0.91 on 22 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: CA$1.23The company is up 37% from its price of CA$0.90 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Dec 17New 90-day high: CA$1.15The company is up 20% from its price of CA$0.96 on 18 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 16% over the same period.Is New 90 Day High Low • Nov 19New 90-day low: CA$0.75The company is down 32% from its price of CA$1.10 on 14 August 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.お知らせ • Nov 06Medicure Inc. to Report Q3, 2020 Results on Nov 11, 2020Medicure Inc. announced that they will report Q3, 2020 results at 10:00 PM, GMT Standard Time on Nov 11, 2020Is New 90 Day High Low • Oct 31New 90-day low: CA$0.80The company is down 25% from its price of CA$1.06 on 31 July 2020. The Canadian market is down 26% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 11% over the same period.Is New 90 Day High Low • Sep 23New 90-day low: CA$0.93The company is down 7.0% from its price of CA$1.00 on 25 June 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.お知らせ • Aug 06Medicure Inc. to Report Q2, 2020 Results on Aug 11, 2020Medicure Inc. announced that they will report Q2, 2020 results on Aug 11, 2020お知らせ • Jul 20Medicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite IndexMedicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite Index このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Medicure は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSXV:MPH - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202631-7-3-3N/A12/31/202529-7-1-1N/A9/30/202526-312N/A6/30/202523-111N/A3/31/202522-222N/A12/31/202422-111N/A9/30/202421-200N/A6/30/202421-311N/A3/31/202422-112N/A12/31/202322-122N/A9/30/202323112N/A6/30/202323211N/A3/31/202323123N/A12/31/202223122N/A9/30/202224333N/A6/30/202223145N/A3/31/202223123N/A12/31/202122-134N/A9/30/202117-701N/A6/30/202116-700N/A3/31/202114-6-1-1N/A12/31/202012-7-2-2N/A9/30/202013-18-5-5N/A6/30/202015-18-16-9N/A3/31/202018-18-20-14N/A12/31/201920-20N/A-15N/A9/30/201925-3N/A-13N/A6/30/201926-3N/A-4N/A3/31/2019280N/A-1N/A12/31/2018294N/A1N/A9/30/20182610N/A-3N/A6/30/20182612N/A24N/A3/31/20182612N/A23N/A12/31/20172711N/A22N/A9/30/2017295N/A30N/A6/30/2017315N/A-3N/A3/31/2017304N/A1N/A12/31/2016294N/A6N/A9/30/2016325N/A5N/A6/30/2016292N/A3N/A3/31/2016252N/A4N/A12/31/2015222N/A0N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MPHの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MPHの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MPHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MPHの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MPHの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MPHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 00:14終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medicure Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Andre UddinResearch Capital CorporationRobert GibsonVentum Financial Corp
New Risk • May 22New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$3.0m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$3.0m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Earnings have declined by 8.0% per year over the past 5 years. Market cap is less than US$10m (CA$11.5m market cap, or US$8.31m).
お知らせ • May 22Medicure Inc. to Report Q1, 2026 Results on May 21, 2026Medicure Inc. announced that they will report Q1, 2026 results at 4:00 PM, US Eastern Standard Time on May 21, 2026
Reported Earnings • Apr 26Full year 2025 earnings released: EPS: CA$0.68 (vs CA$0.10 loss in FY 2024)Full year 2025 results: EPS: CA$0.68. Revenue: CA$28.9m (up 32% from FY 2024). Net loss: CA$7.10m (loss widened CA$6.06m from FY 2024).
お知らせ • Mar 10Medicure Inc., Annual General Meeting, May 21, 2026Medicure Inc., Annual General Meeting, May 21, 2026. Location: manitoba, winnipeg Canada
Reported Earnings • Nov 21Third quarter 2025 earnings released: CA$0.13 loss per share (vs CA$0.065 profit in 3Q 2024)Third quarter 2025 results: CA$0.13 loss per share (down from CA$0.065 profit in 3Q 2024). Revenue: CA$8.16m (up 58% from 3Q 2024). Net loss: CA$1.40m (down 305% from profit in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 14Medicure Inc. to Report Q3, 2025 Results on Nov 19, 2025Medicure Inc. announced that they will report Q3, 2025 results After-Market on Nov 19, 2025
分析記事 • Nov 11Medicure Inc. (CVE:MPH) Surges 29% Yet Its Low P/S Is No Reason For ExcitementMedicure Inc. ( CVE:MPH ) shares have had a really impressive month, gaining 29% after a shaky period beforehand. The...
Reported Earnings • Aug 22Second quarter 2025 earnings released: CA$0.08 loss per share (vs CA$0.12 loss in 2Q 2024)Second quarter 2025 results: CA$0.08 loss per share (improved from CA$0.12 loss in 2Q 2024). Revenue: CA$6.67m (up 29% from 2Q 2024). Net loss: CA$786.0k (loss narrowed 35% from 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 95 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 19Medicure Inc. to Report Q2, 2025 Results on Aug 20, 2025Medicure Inc. announced that they will report Q2, 2025 results After-Market on Aug 20, 2025
Board Change • Jul 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. 5 highly experienced directors. Director James Kinley was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
分析記事 • Jun 21There's No Escaping Medicure Inc.'s (CVE:MPH) Muted Revenues Despite A 26% Share Price RiseMedicure Inc. ( CVE:MPH ) shareholders would be excited to see that the share price has had a great month, posting a...
分析記事 • May 14This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medicure Inc.'s (CVE:MPH) CEOKey Insights Medicure will host its Annual General Meeting on 21st of May Salary of CA$264.0k is part of CEO Albert...
分析記事 • May 07Medicure Inc. (CVE:MPH) Stock Catapults 28% Though Its Price And Business Still Lag The IndustryMedicure Inc. ( CVE:MPH ) shareholders would be excited to see that the share price has had a great month, posting a...
Reported Earnings • Apr 26Full year 2024 earnings released: CA$0.10 loss per share (vs CA$0.088 loss in FY 2023)Full year 2024 results: CA$0.10 loss per share (further deteriorated from CA$0.088 loss in FY 2023). Revenue: CA$21.9m (up 1.0% from FY 2023). Net loss: CA$1.04m (loss widened 13% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 63 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 23Medicure Inc. to Report Fiscal Year 2024 Results on Apr 28, 2025Medicure Inc. announced that they will report fiscal year 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025
分析記事 • Mar 12Medicure Inc.'s (CVE:MPH) Shares Lagging The Industry But So Is The BusinessWhen you see that almost half of the companies in the Biotechs industry in Canada have price-to-sales ratios (or "P/S...
お知らせ • Mar 12Medicure Inc., Annual General Meeting, May 21, 2025Medicure Inc., Annual General Meeting, May 21, 2025. Location: manitoba, winnipeg Canada
Reported Earnings • Nov 26Third quarter 2024 earnings released: EPS: CA$0.07 (vs CA$0.008 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.07 (up from CA$0.008 in 3Q 2023). Revenue: CA$5.15m (up 3.0% from 3Q 2023). Net income: CA$680.0k (up CA$596.0k from 3Q 2023). Profit margin: 13% (up from 1.7% in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 2% per year.
お知らせ • Nov 22Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of DirectorsMedicure Inc. announced that Kimberly Kramchynsky, a member of the Board of Directors, has resigned for personal reasons, effective November 18, 2024.
お知らせ • Nov 19Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024Medicure Inc. announced that they will report Q3, 2024 results After-Market on Nov 25, 2024
Reported Earnings • Aug 16Second quarter 2024 earnings released: CA$0.12 loss per share (vs CA$0.024 profit in 2Q 2023)Second quarter 2024 results: CA$0.12 loss per share (down from CA$0.024 profit in 2Q 2023). Revenue: CA$5.17m (down 14% from 2Q 2023). Net loss: CA$1.22m (down CA$1.47m from profit in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
分析記事 • Jul 31Medicure Inc.'s (CVE:MPH) Price Is Right But Growth Is LackingMedicure Inc.'s ( CVE:MPH ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy right now...
Buy Or Sell Opportunity • Jul 17Now 35% undervalued after recent price dropOver the last 90 days, the stock has fallen 2.9% to CA$1.00. The fair value is estimated to be CA$1.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making.
お知らせ • May 30Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as DirectorMedicure Inc. announced the voting results for the election of directors at its annual meeting of shareholders held earlier May 28, 2024 approved Kimberly Kramchynsky, more commonly known as Kim Kline, is the only newly appointed director. Ms. Kline is currently on the board of BioTalent Canada and the advisory board of RRC Polytech Life Sciences. She is also the past President of the Bioscience Association of Manitoba, a position she held until early 2024, and a former member of the University of Manitoba Faculty of Science Dean's advisory board.
Reported Earnings • May 29First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: CA$5.69m (up 1.2% from 1Q 2023). Net income: CA$51.0k (down 82% from 1Q 2023). Profit margin: 0.9% (down from 5.2% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • May 14Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to CA$1.06. The fair value is estimated to be CA$1.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Meanwhile, the company became loss making.
分析記事 • May 14Estimating The Fair Value Of Medicure Inc. (CVE:MPH)Key Insights Using the 2 Stage Free Cash Flow to Equity, Medicure fair value estimate is CA$1.40 Current share price of...
お知らせ • Apr 21Medicure Inc., Annual General Meeting, May 28, 2024Medicure Inc., Annual General Meeting, May 28, 2024.
Reported Earnings • Apr 12Full year 2023 earnings released: CA$0.088 loss per share (vs CA$0.13 profit in FY 2022)Full year 2023 results: CA$0.088 loss per share (down from CA$0.13 profit in FY 2022). Revenue: CA$21.7m (down 5.9% from FY 2022). Net loss: CA$922.0k (down 168% from profit in FY 2022). Products in clinical trials Phase III: 1 Post-clinical trial products Pre-registration: 1 Approved (during full year): 1 Over the last 3 years on average, earnings per share has increased by 102% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
お知らせ • Apr 05Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024Medicure Inc. announced that they will report fiscal year 2023 results at 4:00 PM, US Eastern Standard Time on Apr 08, 2024
分析記事 • Mar 08Investors Don't See Light At End Of Medicure Inc.'s (CVE:MPH) TunnelWhen close to half the companies in Canada have price-to-earnings ratios (or "P/E's") above 15x, you may consider...
New Risk • Jan 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (CA$12.0m market cap, or US$8.90m). Minor Risk Profit margins are more than 30% lower than last year (4.7% net profit margin).
New Risk • Jan 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: CA$11.1m (US$8.24m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (CA$11.1m market cap, or US$8.24m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Profit margins are more than 30% lower than last year (4.7% net profit margin).
Valuation Update With 7 Day Price Move • Jan 15Investor sentiment deteriorates as stock falls 24%After last week's 24% share price decline to CA$1.06, the stock trades at a trailing P/E ratio of 10.2x. Average trailing P/E is 18x in the Biotechs industry in North America. Total loss to shareholders of 23% over the past three years.
Valuation Update With 7 Day Price Move • Dec 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CA$1.32, the stock trades at a trailing P/E ratio of 12.8x. Average trailing P/E is 17x in the Biotechs industry in North America. Total returns to shareholders of 55% over the past three years.
お知らせ • Nov 24Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric DiseaseMedicure Inc. announced that the FDA provides complete approval to enroll patients in its pivotal Phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphateoxidase (PNPO) deficiency. The study involves approximately 10 patients at sites in the United States and Australia, and the Company is seeking marketing approval initially in those countries. The U.S. Food and Drug Administration ("FDA") has granted both Orphan Drug Designation and Rare Pediatric Disease Designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency ("EMA") has granted Orphan Drug Designation toMC-1 for the treatment of PNPO deficiency. Under the Food and Drug Administration Safety and Innovation Act (FDASIA) passed into federal law in 2012, the FDA grants a Rare Pediatric Disease Designation for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals from birth to 18 years of age, with a prevalence of less than 200,000 people in the United States. If a new drug application ("NDA") for MC-1 for patients with PNPO deficiency is approved, the Company may be eligible to receive a priority review voucher ("PRV") from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application.
Reported Earnings • Nov 24Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.11 in 3Q 2022)Third quarter 2023 results: EPS: CA$0.01 (down from CA$0.11 in 3Q 2022). Revenue: CA$5.00m (down 5.4% from 3Q 2022). Net income: CA$84.0k (down 93% from 3Q 2022). Profit margin: 1.7% (down from 21% in 3Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has only increased by 22% per year, which means it is significantly lagging earnings growth.
New Risk • Nov 23New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 4.7% Last year net profit margin: 12% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (4.7% net profit margin). Market cap is less than US$100m (CA$15.7m market cap, or US$11.4m).
New Risk • Nov 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (CA$14.8m market cap, or US$10.7m).
Valuation Update With 7 Day Price Move • Oct 30Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CA$1.50, the stock trades at a trailing P/E ratio of 7.4x. Average trailing P/E is 15x in the Biotechs industry in North America. Total returns to shareholders of 88% over the past three years.
分析記事 • Aug 28We Ran A Stock Scan For Earnings Growth And Medicure (CVE:MPH) Passed With EaseIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Reported Earnings • Jul 30Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.067 loss in 2Q 2022)Second quarter 2023 results: EPS: CA$0.02 (up from CA$0.067 loss in 2Q 2022). Revenue: CA$5.99m (up 4.3% from 2Q 2022). Net income: CA$253.0k (up CA$936.0k from 2Q 2022). Profit margin: 4.2% (up from net loss in 2Q 2022). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 114% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 25Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023Medicure Inc. announced that they will report Q2, 2023 results After-Market on Jul 28, 2023
New Risk • Jul 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (CA$13.5m market cap, or US$10.2m).
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to CA$1.13, the stock trades at a trailing P/E ratio of 10.1x. Average trailing P/E is 13x in the Biotechs industry in North America. Total returns to shareholders of 5.6% over the past three years.
Valuation Update With 7 Day Price Move • Jun 23Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CA$1.35, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 12x in the Biotechs industry in North America. Total returns to shareholders of 36% over the past three years.
Reported Earnings • May 28First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.047 in 1Q 2022)First quarter 2023 results: EPS: CA$0.03 (down from CA$0.047 in 1Q 2022). Revenue: CA$5.63m (down 1.5% from 1Q 2022). Net income: CA$290.0k (down 40% from 1Q 2022). Profit margin: 5.2% (down from 8.4% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • May 05Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to CA$1.01, the stock trades at a trailing P/E ratio of 7.6x. Average trailing P/E is 14x in the Biotechs industry in North America. Total loss to shareholders of 19% over the past three years.
Valuation Update With 7 Day Price Move • Apr 19Investor sentiment improves as stock rises 20%After last week's 20% share price gain to CA$1.39, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 14x in the Biotechs industry in North America. Total loss to shareholders of 17% over the past three years.
Reported Earnings • Apr 08Full year 2022 earnings released: EPS: CA$0.13 (vs CA$0.071 loss in FY 2021)Full year 2022 results: EPS: CA$0.13 (up from CA$0.071 loss in FY 2021). Revenue: CA$23.1m (up 6.1% from FY 2021). Net income: CA$1.37m (up CA$2.09m from FY 2021). Profit margin: 5.9% (up from net loss in FY 2021). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
お知らせ • Feb 02Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of DirectorsMedicure Inc. announced that Gerald McDole, a member of the Board of Directors, has resigned from his position, effective January 31, 2023. Mr. McDole was originally appointed a director on January 16, 2004.
Valuation Update With 7 Day Price Move • Jan 17Investor sentiment improved over the past weekAfter last week's 18% share price gain to CA$1.25, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 14x in the Biotechs industry in North America. Total loss to shareholders of 64% over the past three years.
Recent Insider Transactions • Dec 23Founder recently bought CA$67k worth of stockOn the 16th of December, Albert Friesen bought around 67k shares on-market at roughly CA$1.00 per share. This transaction amounted to 2.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Albert has been a buyer over the last 12 months, purchasing a net total of CA$184k worth in shares.
分析記事 • Nov 30Medicure's (CVE:MPH) Earnings Are Weaker Than They SeemMedicure Inc.'s ( CVE:MPH ) robust earnings report didn't manage to move the market for its stock. We did some digging...
Reported Earnings • Nov 25Third quarter 2022 earnings released: EPS: CA$0.11 (vs CA$0.092 loss in 3Q 2021)Third quarter 2022 results: EPS: CA$0.11 (up from CA$0.092 loss in 3Q 2021). Revenue: CA$5.29m (up 7.5% from 3Q 2021). Net income: CA$1.11m (up CA$2.06m from 3Q 2021). Profit margin: 21% (up from net loss in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
お知らせ • Nov 18Medicure Inc. to Report Q3, 2022 Results on Nov 25, 2022Medicure Inc. announced that they will report Q3, 2022 results on Nov 25, 2022
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Independent Director Brent Fawkes was the last director to join the board, commencing their role in 2013. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 25Second quarter 2022 earnings released: CA$0.067 loss per share (vs CA$0.062 loss in 2Q 2021)Second quarter 2022 results: CA$0.067 loss per share (down from CA$0.062 loss in 2Q 2021). Revenue: CA$5.75m (up 13% from 2Q 2021). Net loss: CA$683.0k (loss widened 6.9% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment improved over the past weekAfter last week's 44% share price gain to CA$1.37, the stock trades at a trailing P/E ratio of 17.5x. Average trailing P/E is 16x in the Biotechs industry in North America. Total loss to shareholders of 70% over the past three years.
お知らせ • Aug 18Medicure Inc. to Report Q2, 2022 Results on Aug 24, 2022Medicure Inc. announced that they will report Q2, 2022 results After-Market on Aug 24, 2022
Valuation Update With 7 Day Price Move • Jul 27Investor sentiment improved over the past weekAfter last week's 29% share price gain to CA$1.16, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 16x in the Biotechs industry in North America. Total loss to shareholders of 77% over the past three years.
お知らせ • Jun 21Medicure Inc. Appoints James Kinley as DirectorMedicure Inc. announced that James Kinley was elected as director at its Annual General Meeting of shareholders held on June 16, 2022.
Reported Earnings • Jun 01First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2022 results: EPS: CA$0.047 (up from CA$0.10 loss in 1Q 2021). Revenue: CA$5.72m (up 16% from 1Q 2021). Net income: CA$482.0k (up CA$1.53m from 1Q 2021). Profit margin: 8.4% (up from net loss in 1Q 2021). Revenue missed analyst estimates by 46%. Earnings per share (EPS) exceeded analyst estimates. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
お知らせ • May 31Medicure Inc. Appoints Haaris Uddin as Chief Financial Officer, Effective June 1, 2022Medicure Inc. announced the appointment of Mr. Haaris Uddin (CPA, B.Comm.) as Chief Financial Officer, effective June 1, 2022. Mr. Uddin as Chief Financial Officer, he began his career with Ernst & Young LLP as a senior accountant in assurance services and brings experience in public company reporting within the life sciences industry in both Canada and the United States.
Reported Earnings • Apr 29Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: CA$0.07 loss per share (up from CA$0.64 loss in FY 2020). Revenue: CA$21.7m (up 87% from FY 2020). Net loss: CA$727.0k (loss narrowed 89% from FY 2020). Post-clinical trial products Pre-registration: 1 Revenue missed analyst estimates by 46%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 45% per year, which means it is performing significantly worse than earnings.
Board Change • Apr 28Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 6 highly experienced directors. Independent Director Brent Fawkes was the last director to join the board, commencing their role in 2013. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 16Medicure Inc., Annual General Meeting, Jun 16, 2022Medicure Inc., Annual General Meeting, Jun 16, 2022.
お知らせ • Nov 24Medicure Plans to Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly to Millions of AmericansMedicure Inc. announced that it is planning to launch a national direct-to-consumer E-Commerce pharmacy platform through its subsidiary, Marley Drug™ pharmacy, before the end of 2021. Marley Drug's new E-Commerce website will be a platform where FDA approved medications can be purchased at discount prices by Americans for home delivery in all 50 States, including ZYPITAMAG® (pitavastatin) tablets. A primary goal of the platform is to bypass the traditional framework run by health insurers and pharmacy benefit managers that have made access to affordable medications challenging for many Americans, including both generic and branded products such as ZYPITAMAG. More than 120 million uninsured and underinsured Americans struggle to access affordable medications and are looking for a trusted and convenient source to fill their prescriptions. Marley Drug will offer industry leading pricing on more than 100 of the most commonly prescribed generic medications with free nationwide delivery. The platform will focus on ease-of-use and customer service, and is differentiated by being able to ship to every US state. Notably, the pharmacy platform addresses 'pharmacy deserts' that exist across the country. A 'pharmacy desert' is defined as a geographic area where Americans can't fill a prescription within a half-a-mile of their homes (for low-income people without cars), and a mile for others. This lack of quick access to a pharmacy affects many Americans.
Reported Earnings • Nov 24Third quarter 2021 earnings: EPS and revenues miss analyst expectationsThird quarter 2021 results: CA$0.09 loss per share (up from CA$0.098 loss in 3Q 2020). Revenue: CA$4.92m (up 39% from 3Q 2020). Net loss: CA$946.0k (loss narrowed 9.6% from 3Q 2020). Revenue missed analyst estimates by 46%. Earnings per share (EPS) also missed analyst estimates by 100%. Earnings per share (EPS) missed analyst estimates by 100%. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 42% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 28Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.002 profit in 2Q 2020)The company reported a mediocre second quarter result with weaker earnings and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CA$5.09m (up 90% from 2Q 2020). Net loss: CA$639.0k (down CA$658.0k from profit in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 33 percentage points per year, which is a significant difference in performance.
分析記事 • Jun 15Here's Why Shareholders Should Examine Medicure Inc.'s (CVE:MPH) CEO Compensation Package More CloselyThe results at Medicure Inc. ( CVE:MPH ) have been quite disappointing recently and CEO Albert Friesen bears some...
Executive Departure • May 18CFO & Secretary has left the companyOn the 15th of May, James Kinley's tenure in the role of CFO & Secretary ended. As of December 2020, James personally held only 47.10k shares (CA$56k worth at the time). James is the only executive to leave the company over the last 12 months.
Reported Earnings • May 12First quarter 2021 earnings releasedThe company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: CA$4.94m (up 64% from 1Q 2020). Net loss: CA$1.05m (loss narrowed 28% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
Reported Earnings • Apr 24Full year 2020 earnings releasedThe company reported a decent full year result with reduced losses and improved control over expenses, although revenues were weaker. Full year 2020 results: Revenue: CA$11.6m (down 42% from FY 2019). Net loss: CA$6.85m (loss narrowed 65% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 93 percentage points per year, which is a significant difference in performance.
Is New 90 Day High Low • Feb 23New 90-day high: CA$1.70The company is up 127% from its price of CA$0.75 on 24 November 2020. The Canadian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period.
お知らせ • Jan 28Medicure Announces Early Completion of Enrollment for iSPASMMedicure Inc. announce the early completion of iSPASM, a randomized, double-blind, single-center, Phase 1/2a trial aimed at assessing the safety of long-term (7-day) use of AGGRASTAT® (tirofiban hydrochloride) injection (an intravenous GP IIb/IIIa inhibitor) vs. placebo in patients with aneurysmal subarachnoid hemorrhage (aSAH) (NCT03691727). The primary endpoint in the 30 patient study was hemorrhagic changes evident on head CT and/or MRI assessed by the rates of symptomatic and asymptomatic bleeding. iSPASM was funded by an unrestricted educational grant from Medicure. This study does not imply efficacy of AGGRASTAT® in patients with aSAH. Please note that the use of AGGRASTAT® in neurointerventions has not been approved by the FDA. As of this time, neither AGGRASTAT® nor any of the GP IIb/IIIa inhibitors are indicated for the use in stroke patients. AGGRASTAT® is approved for use in NSTE-ACS patients. Refer to Important Safety Information below and the U.S. Prescribing Information for complete product information.
Is New 90 Day High Low • Jan 23New 90-day high: CA$1.65The company is up 81% from its price of CA$0.91 on 22 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: CA$1.23The company is up 37% from its price of CA$0.90 on 06 October 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Dec 17New 90-day high: CA$1.15The company is up 20% from its price of CA$0.96 on 18 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 16% over the same period.
Is New 90 Day High Low • Nov 19New 90-day low: CA$0.75The company is down 32% from its price of CA$1.10 on 14 August 2020. The Canadian market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 19% over the same period.
お知らせ • Nov 06Medicure Inc. to Report Q3, 2020 Results on Nov 11, 2020Medicure Inc. announced that they will report Q3, 2020 results at 10:00 PM, GMT Standard Time on Nov 11, 2020
Is New 90 Day High Low • Oct 31New 90-day low: CA$0.80The company is down 25% from its price of CA$1.06 on 31 July 2020. The Canadian market is down 26% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 11% over the same period.
Is New 90 Day High Low • Sep 23New 90-day low: CA$0.93The company is down 7.0% from its price of CA$1.00 on 25 June 2020. The Canadian market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 3.0% over the same period.
お知らせ • Aug 06Medicure Inc. to Report Q2, 2020 Results on Aug 11, 2020Medicure Inc. announced that they will report Q2, 2020 results on Aug 11, 2020
お知らせ • Jul 20Medicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite IndexMedicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite Index